2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物工程股份有限公司2024年年度权益分派方案已获2025年4月25日召 开的2024年度股东大会审议通过，现将权益分派事宜公告如下： 证券代码：002007 证券简称：华兰生物 公告编号：2025-020 华兰生物工程股份有限公司 一、股东大会审议通过利润分配方案的情况 1、公司于 2025 年 4 月 25 日召开的 2024 年度股东大会审议通过了《关于 2024 年度利润分配的议案》，公司 2024 年度利润分配方案为：以总股本 1,828,780,926 股为基数， 向全体股东每 10 股派现金股利 2 元（含税），总计 分配 365,756,185.20 元；除上述现金分红外，本次分配公司不送红股，不实施 资本公积金转增股本。若在董事会决议公告之日起至实施权益分派股权登记日期 间，公司总股本由于股权激励注销原因而发生变化的，公司将按照分配比例不变 的原则对分配总额进行调整。 2、自上述利润分配方案披露至实施期间，公司于 2025 年 5 月 19 日完成回 购注销 ...

Group 1 - The National Vaccine and Biotechnology Index (980015) has seen a strong increase of 2.39% as of May 29, 2025, with notable gains in constituent stocks such as Zhaoyan New Drug (603127) up 9.99%, Yifan Pharmaceutical (002019) up 9.17%, and Dizhe Pharmaceutical (688192) up 8.73% [1] - The Biovaccine ETF (159657) rose by 2.28%, with the latest price reported at 0.63 yuan [2] - The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will take place from May 30 to June 3, 2025, in Chicago, showcasing the development of oncology research in China, with over 70 studies from Chinese scholars selected for presentation [2] Group 2 - The top ten weighted stocks in the National Vaccine and Biotechnology Index (980015) as of April 30, 2025, include Fosun Pharma (600196), Changchun High-tech (000661), and others, collectively accounting for 63.18% of the index [3] - The Biovaccine ETF closely tracks the National Vaccine and Biotechnology Index, which consists of 50 companies involved in the biotechnology industry, reflecting the overall performance of quality listed companies in the sector [2]

Group 1: Company Performance and Growth Drivers - Luoyang Molybdenum's Secretary Xu Hui highlighted the company's focus on geological exploration and resource upgrades, with a copper production guidance of 600,000 to 660,000 tons for 2025 [1] - Hanwei Technology's subsidiary Nengsida is expanding its production capacity for flexible sensors, with a new production line expected to be operational in the second half of the year [2] - Multiple Fluoride's Secretary Peng Chao noted that the price of lithium hexafluorophosphate is stabilizing, which is expected to enhance the company's performance [2] Group 2: Market Value Management Strategies - Zhongyuan Environmental emphasized the importance of market value management, focusing on compliance and innovation to enhance investor returns [4] - Ming Tai Aluminum's Secretary Lei Peng discussed the company's commitment to high-end manufacturing and low-carbon economy, aiming to improve its market value through various initiatives [4] - AVIC Optoelectronics has implemented several market value management measures, including a planned cash dividend of 1.695 billion yuan for 2024, representing a 50.52% payout ratio [5]

Core Viewpoint - The company is actively managing its financing and operational strategies to strengthen its position in the blood products and vaccine markets while addressing investor inquiries regarding its cash reserves and short-term loans [1][2]. Group 1: Financial Management - The company has a short-term loan of 1 billion, which is a normal financing behavior based on its operational needs, with plans to repay 600 million by June 2025 [1]. - After the repayment, the remaining financing will consist of bank acceptance discount financing [1]. Group 2: Business Strategy and Growth - The company aims to solidify its position in the blood products industry by increasing plasma collection, improving plasma utilization rates, optimizing product structure, and enhancing the production and R&D of urgently needed products [1]. - The company is focusing on vaccine development, including products like quadrivalent influenza virus split vaccine and freeze-dried human rabies vaccine, to strengthen its vaccine business [1]. - The company is committed to innovation in drug development, targeting treatments for critical diseases such as cancer and autoimmune diseases, while expanding strategic partnerships with domestic and international firms [1]. Group 3: Industry Context - The company operates 34 single plasma collection stations and plans to collect 1,586.37 tons of plasma in 2024, representing an 18.18% increase from the previous year [2]. - Currently, three major companies are developing recombinant human albumin, none of which have obtained drug registration certificates or market approval, indicating potential market opportunities if successful [2].

证券代码：002007 证券简称：华兰生物 公告编号：2025-019 华兰生物工程股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责 任。 特别提示： （1）华兰生物工程股份有限公司（以下简称"公司"）本次回购注销的限 制性股票涉及83名激励对象，回购注销的股票数量1,324,260股，占回购注销前 公司股份总数1,828,780,926股的0.0724％。 （2）限制性股票回购价格：10.59元。 （3）截至本公告披露日，公司已在中国证券登记结算有限责任公司深圳分 公司完成上述限制性股票的回购注销手续。回购注销完成后，公司总股本由 手续。 华兰生物工程股份有限公司（以下简称"公司"）于2025年3月28日召开第 八届董事会第十五次会议及第八届监事会第十五次会议，并于2025年4月25日召 开2024年度股东大会，审议通过了《关于回购注销2023年限制性股票激励计划 部分限制性股票暨调整回购价格的议案》，具体内容详见公司于2025年3月29日 披露在《证券时报》和巨潮资讯网的《关于回购注销2023年限制性股票激励 ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-019 华兰生物工程股份有限公司 关于部分限制性股票回购注销完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责 特别提示： （1）华兰生物工程股份有限公司（以下简称"公司"）本次回购注销的限 制性股票涉及83名激励对象，回购注销的股票数量1,324,260股，占回购注销前 公司股份总数1,828,780,926股的0.0724％。 （2）限制性股票回购价格：10.59元。 （3）截至本公告披露日，公司已在中国证券登记结算有限责任公司深圳分 公司完成上述限制性股票的回购注销手续。回购注销完成后，公司总股本由 1,828,780,926股减至1,827,456,666股。公司将依法办理相关的工商变更登记 手续。 华兰生物工程股份有限公司（以下简称"公司"）于2025年3月28日召开第 八届董事会第十五次会议及第八届监事会第十五次会议，并于2025年4月25日召 开2024年度股东大会，审议通过了《关于回购注销2023年限制性股票激励计划 部分限制性股票暨调整 ...

华兰生物 20250519 摘要 • 公司通过稳定产品价格、保障医院供应和调整销售策略，在行业压力下实 现了产销量和利润的持续增长。2024 年精品价格维持在 700 元，人才价 格在 420-450 元，与竞品降价形成对比。 • 公司对院内与院外市场供应比例无严格考核，但保证医院和药店供应，并 通过销售人员走访确保供应链稳定。疫情期间对医院维护较好，人血白蛋 白和静注人免疫球蛋白推广顺畅。 • 公司出厂价保持稳定，通过定期走访和流向查看约束经销商，确保医院供 货。人血白蛋白和精品自疫情前至今出厂价基本不变，经销商断供可能导 致市场份额被抢占。 • 疫情期间人血白蛋白和精品等产品在外部市场出现非正常高价，但公司出 厂价基本稳定，销量持续增长。人血白蛋白最高限价为 378 元，疫情期间 价格维持高位，2024 年第三季度后逐渐回归常态。 • 进口人血白蛋白关税提高 10%，导致成本增加，可能导致终端价格回升。 目前出厂价与终端架构价较为接近，配送商业公司仍有利润空间，降价可 能性较低。 Q&A 今年（2025 年）血制品行业面临的主要压力是什么？贵公司在一季度业绩表 现优于行业平均水平的原因有哪些？ 今年（20 ...

Core Viewpoint - The disease prevention and control industry in China is experiencing growth due to increased public awareness, government funding, and advancements in biotechnology and data analysis, leading to improved efficiency in disease management [1][13]. Summary by Sections Industry Overview - Disease prevention and control is a crucial part of public health, focusing on reducing the occurrence and spread of diseases through scientific methods [3]. - Effective disease control can lower healthcare costs, enhance quality of life, and support economic stability [3]. Industry Development - The scale of China's disease prevention and control industry has been on the rise, with central government funding for disease control projects increasing from 17.526 billion to 20.38 billion from 2020 to 2022, followed by a projected recovery to 20.881 billion in 2024, marking an 18.06% year-on-year increase [1][13]. - The number of disease control centers in China has grown from 3,376 in 2021 to 3,429 in 2024, enhancing public health emergency management capabilities [11]. Policy Initiatives - Recent policies emphasize strengthening disease control institutions, enhancing core functions, and promoting scientific research and public health cooperation [5][7]. - The 2024-2025 National Disease Prevention and Control Action Plan encourages local institutions to engage in applied research and technology transfer [5][7]. Competitive Landscape - The disease prevention market in China is competitive, with key players including Fosun Pharma, Kangtai Biological, and Zhifei Biological, which are focusing on innovation and service quality to capture market share [15][19]. Industry Trends - The chronic disease management market is expected to grow significantly due to the aging population and increasing prevalence of chronic diseases, which currently account for 88% of total deaths in China [21]. - Technological innovations such as big data, AI, and IoT are set to transform disease prevention and control, enhancing monitoring and decision-making processes [22]. - The integration of sports and health ("body-health integration") is emerging as a new trend, promoting physical activity as a preventive measure against chronic diseases [23].

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology industry, suggesting it is at a turning point for profit improvement and has high allocation value [3][4]. Core Insights - The pharmaceutical sector is showing signs of recovery after three years of declining profitability, with a notable increase in net profit margin by 0.3% in Q1 2025 compared to the previous year [3][5]. - Key sub-sectors such as CXO, innovative drugs, biological products, private hospitals, and medical consumables have demonstrated strong performance in Q1 2025, with several leading companies exceeding expectations [3][4]. - The report recommends focusing on sub-sectors and companies with clear upward trends in performance, including innovative drugs and CXO services [3][4]. Overall Performance of the Sector - In 2024, 473 A-share pharmaceutical companies achieved total revenue of 24,588 billion yuan, a year-on-year decrease of 0.9%, and a net profit of 1,412 billion yuan, down 12.1% [3][5]. - For Q1 2025, the sector reported revenue of 6,104 billion yuan, a decline of 4.2% year-on-year, with net profit at 487 billion yuan, down 8.7% [3][5]. Sub-sector Performance - The CXO sector has shown a turnaround since Q4 2024, with Q1 2025 revenue of 225 billion yuan, reflecting an 11.6% year-on-year increase, and net profit of 50 billion yuan, up 72.8% [3][23]. - The innovative drug sector continues to grow rapidly, with leading companies like Heng Rui Medicine and Bai Jie Shen Zhou performing above expectations [3][18]. - The hospital sector is beginning to show signs of recovery, with Q1 2025 revenue of 144 billion yuan, a year-on-year increase of 4.9%, and net profit of 11 billion yuan, up 19.2% [3][28]. Investment Analysis - The report emphasizes the importance of investing in sectors and companies that are showing clear signs of upward trends, particularly in innovative drugs and CXO services [3][4]. - Specific companies recommended for investment include Heng Rui Medicine, Bai Jie Shen Zhou, and Wu Xi AppTec in the innovative drug and CXO sectors [3][4].

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，华兰生物工程股份有限公司（以下简称 "公司"）定于2025年5月22日（周四）15:25-16:55参加在全景网举办的河南辖 区上市公司2025年投资者网上集体接待日活动，本次活动将采用网络远程的方式 举行，投资者可登录"全景·路演天下"（http://rs.p5w.net）参与本次互动 交流。 出席本次网上集体接待日活动的人员有：公司财务总监兼董事会秘书谢军民 先生、证券事务代表娄源成先生，欢迎广大投资者积极参与！ 特此公告。 华兰生物工程股份有限公司董事会 证券代码：002007 证券简称：华兰生物 公告编号：2025-018 华兰生物工程股份有限公司 关于参加河南辖区上市公司 2025年投资者网上集体接待日活动的公告 2025年5月17日 ...